FDA-restricted claim language on Amazon, the 2026 enforcement pattern

FDA-restricted claim enforcement on Amazon shifted measurably in early 2026. Suppressions on health and personal-care SKUs are landing faster, the language patterns Amazon’s compliance team flags are broader than they were in 2024, and the recovery time on suppression appeals is longer, typically 14-21 days against the 5-7 days we used to see. For brands in supplements, OTC, topicals, and condition-targeted categories, this means the cost of getting claim language wrong has risen sharply.

This is the playbook we run on every health-category account: what changed, what’s actually risky in 2026, and what to rewrite before the next round of suppressions hits.

What changed in early 2026

Three operational shifts inside Amazon’s compliance pipeline:

First, automated detection got more confident. The keyword and phrase-pattern matching has expanded beyond explicit disease claims (“treats arthritis,” “cures diabetes”) into structure-function-adjacent language that previously slid through. We’ve watched listings get suppressed for “supports healthy joint mobility in dogs with chronic discomfort”, language that was acceptable in 2024 because the structure-function form was respected. The 2026 model reads “chronic discomfort” as a disease descriptor and flags the listing.

Second, the suppression cascade tightened. In 2024, a single bullet point with non-compliant language would get the bullet edited or the listing temporarily suspended. In 2026, the same trigger results in a full-listing suppression, with the entire SKU pulled from search until the brand re-submits. The blast radius is bigger.

Third, appeal turnaround slowed. The compliance team is processing more cases with the same headcount; recovery times are running 14-21 days instead of the 5-7 we logged in 2024. For a brand running paid traffic into a suppressed SKU, that’s a meaningful budget hit before the listing comes back.

Three categories of risk in 2026

Category 1: Disease-state language. Anything that names or describes a disease, condition, or symptom in a way that implies your product treats it. The 2024 boundary was relatively explicit (don’t say “treats arthritis”). The 2026 boundary catches softer phrasings: “for joint discomfort,” “supports relief from occasional inflammation,” “for skin issues caused by environmental allergens.” The pattern Amazon now reads: any phrase that combines a structure-function verb (supports, helps, aids) with a description that pattern-matches a medical condition.

What’s still safe: the canonical structure-function form (“supports joint health,” “helps maintain healthy mobility”). What’s newly risky: anything that adds a condition modifier on top of the structure-function form.

Category 2: Quantitative outcome claims. Numerical claims about effect, “reduces inflammation by 30%,” “improves mobility within 14 days,” “clinically proven to lower X”, are now flagged regardless of whether the claim is substantiated. The substantiation matters for FDA enforcement; it doesn’t matter for Amazon’s compliance bot. The bot reads the pattern of “[verb] [outcome] by [number]” or “[verb] [outcome] within [timeframe]” and flags it.

If you have clinical data that supports a quantitative claim, the right place for it is in the clinical-trial citation language, not in the bullet points. Move quantitative claims to “studies have observed” framings in the A+ body copy, not in the headline real estate.

Category 3: Comparison-to-pharmaceutical language. Anything that positions your supplement or OTC against a pharmaceutical category, “natural alternative to NSAIDs,” “non-prescription approach to…”, is now flagged consistently. This was inconsistent in 2024 and is consistent in 2026. The mental model: you can describe what your product does, you cannot describe what your product replaces.

What we rewrite first

The audit we run on every new health-category account, in priority order:

First, every Title and Bullet 1. These get the most algorithmic attention and the most compliance scrutiny. We strip any language that combines a structure-function verb with a condition modifier. Re-cast in the canonical form.

Second, A+ headline modules. Same treatment, Cosmo reads them as the page’s primary statements, and so does the compliance bot. The body copy under the headline can be more nuanced, but the headline itself needs to land cleanly inside the structure-function boundary.

Third, FAQ modules. These are where brands often hide aggressive claims, on the theory that FAQ tone permits more specificity. The 2026 enforcement pattern reads FAQ language with the same scrutiny as bullets. If you have a quantitative outcome claim in your FAQ, move it to a clinical-citation footnote in the A+ body and replace the FAQ entry with structure-function language.

Fourth, image text. We see this missed constantly. Embedded text in lifestyle images and infographics (“clinically shown to reduce X”) gets read by Amazon’s image-OCR pipeline and flagged through the same compliance route as text claims. If your A+ images contain claim language, audit them.

Fifth, backend keywords. Less scrutiny here, but disease-name keywords (“arthritis,” “anxiety,” “depression”) in your backend search terms are flagged as a relevance-and-compliance issue and can affect listing visibility even if they don’t trigger suppression. Strip them.

The structure-function safe form

The boundary FDA articulates is structure-function vs. disease claim, and Amazon’s compliance pattern follows it. The structure-function form: your product affects the structure or function of the body, it does not treat, cure, prevent, or diagnose any disease.

Phrasings that survive 2026 enforcement:

• “Supports healthy [body system]”
• “Helps maintain [normal function]”
• “Promotes [healthy state]”
• “Designed for [users with general lifestyle context]”

Phrasings that don’t:

• “Supports [body system] in those with [condition]”
• “Helps relieve [symptom of a condition]”
• “For [condition-adjacent demographic]”
• “Reduces [outcome] by [amount]”

The discipline is keeping the structure-function form pure, not adding qualifiers that drift into disease territory.

What this costs if you get it wrong

We modeled the cost of a 14-day suppression on a $3M-revenue health SKU running paid traffic. The impact: ~$48K in lost GMV (revenue gone for 14 days, not all recoverable on re-listing), ~$12K in wasted ad spend (driving traffic to a suppressed page), ~$6K in agency/in-house ops time managing the appeal, plus 30-90 days of organic-share recovery once the listing returns (Cosmo deprioritizes recently-suppressed SKUs even after compliance approval).

Total: $66K + indirect organic-share cost + appeals workload. On a SKU doing $3M/yr, a single suppression costs roughly 2.2% of annual revenue. Two in a year and you’ve lost a margin point.

What to do this quarter

Three things, in priority:

Audit your top 10 SKUs for the three risk categories. Title, Bullet 1, A+ headline, FAQ, image text. Anything that violates the structure-function-pure form gets rewritten in the next 30 days.

Move quantitative claims out of the headline tier. Substantiated clinical data still has a place, but in the clinical-citation footnote in the A+ body, not in bullets or A+ banners.

Treat the audit as ongoing, not one-time. Compliance patterns shift; what slid through in March may not in August. The brands compounding in this category are treating their catalog as a versioned product, with compliance rewrites as a recurring line item rather than a fire drill. That’s the same mindset the Cosmo-aware A+ rebuild requires for ranking, apply it to compliance and you’re running both loops with the same operating system.

Get an audit, we’ll flag your highest-risk claim language and prioritize the rewrites.